Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
It’s an AB-rated generic therapeutic version of Durezol
It had an estimated market size of US $ 32 million as of June 2021
Sumatriptan Injection USP is indicated in adults for acute treatment of migraine with or without aura, and acute treatment of cluster headache
The company has a cumulative total of 147 ANDA approvals (129 final approvals and 18 tentative approvals) from USFDA
Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
Subscribe To Our Newsletter & Stay Updated
